



or FOLFOX7 with oxaliplatin in a stop-and-Go fashion in advanced colorectal cancer--a GERCOR study. *J Clin Oncol.* 2006; 24(3): 394–400.

13. Chibaudel B, Maindrault-Goebel F, Lledo G, et al. Can chemotherapy be discontinued in unresectable metastatic colorectal cancer? The GERCOR OPTIMO2 Study. *J Clin Oncol.* 2009; 27(34): 5727–5733. doi:10.1200/JCO.2009.23.4344.

14. Simkens LH, van Tinteren H, May A, et al. Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3): a phase 3 randomised controlled trial of the Dutch Colorectal Cancer Group. *Lancet* 2015; 385(9980): 1843–1852.

15. Bennouna J, Sastre J, Arnold D, et al. Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial. *Lancet Oncol.* 2013; 14(1): 29–37.

16. Van Cutsem E, Taberero J, Lakomy R, et al. Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen. *J Clin Oncol.* 2012; 30(28): 3499–3506.

17. Taberero J, Yoshino T, Cohn AL, et al. RAISE Study Investigators. Ramucirumab versus placebo in combination with second – line FOLFIRI in patients with metastatic colorectal

carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and fluoropyrimidine (RAISE): a randomised, double blind, multicentre, phase 3 study. *Lancet Oncol* 2015; 16: 499–508.

18. Hecht JR, Cohn A, Dakhil S, et al. SPIRITT: A randomized, multicenter, phase II study of panitumumab with FOLFIRI and bevacizumab with FOLFIRI as second-line treatment in patients with unresectable wild type KRAS metastatic colorectal cancer. *Clin Colorectal Cancer* 2015; 14: 72–80.

19. Bennouna J, Hirt S, Borg C, et al. Bevacizumab or cetuximab plus chemotherapy after progression with bevacizumab plus chemotherapy in patients with wild-type KRAS metastatic colorectal cancer.: Final analysis of a French randomized, multicenter, phase II study (PRODIGE 18). *Ann Oncol* 2017; 28(suppl_5)

20. Grothey A, Van Cutsem E, Sobrero A, et al. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. *Lancet.* 2013; 381(9863): 303–312.

21. Bekaii-Saab TS, Ou FS, Ahn DH, et al. Regorafenib dose-optimisation in patients with refractory metastatic colorectal cancer (ReDOS): a randomised, multicentre, open-label, phase 2 study. *Lancet Oncol.* 2019; 20(8): 1070–1082.